EXFO Inc. (Nasdaq:EXFO) reported record sales and bookings for its first quarter ended November 30, 2010, with total sales and GAAP net earnings above the company’s guidance range.
Total sales, including a one-month revenue contribution from the divested Life Sciences and Industrial Division, increased 48.5% to US$67.6 million in the first quarter of fiscal 2011 from US$45.6 million in the first quarter of 2010 and 3.7% from US$65.2 million in the fourth quarter of 2010. Management had forecasted total sales between US$61 and US$66 million for the first quarter of 2011.
Telecom sales increased 62.9% to US$65.7 million in the first quarter of 2011 from US$40.3 million in the first quarter of 2010 and 12.1% from US$58.6 million in the fourth quarter of 2010. NetHawk Oyj, which was acquired in mid-March 2010, contributed US$6.4 million to EXFO’s revenues in the first quarter of 2011. Consequently, organic telecom sales increased 47.0% year-over-year.
Telecom bookings improved 92.0% to US$89.8 million in the first quarter of fiscal 2011 from US$46.8 million in the same period last year and 60.9% from US$55.8 million in the fourth quarter of 2010. The company’s telecom book-to-bill ratio was 1.37 in the first quarter of 2011.
Telecom gross margin reached 62.2% of sales in the first quarter of fiscal 2011 compared to 65.2% in the first quarter of 2010 and 64.8% in the fourth quarter of 2010.
EXFO is among the leading providers of next-generation test and service assurance solutions for wireless and wireline network operators and equipment manufacturers in the global telecommunications industry. The company offers innovative solutions for the development, installation, management and maintenance of converged, IP fixed and mobile networks — from the core to the edge. Key technologies supported include 3G, 4G/LTE, IMS, Ethernet, OTN, FTTx, and various optical technologies (accounting for an estimated 35% of the portable fiber-optic test market). EXFO has a staff of approximately 1600 people in 25 countries, supporting more than 2000 telecom customers worldwide.
Power3 Medical Products, Inc. (OTC.BB:PWRM) is a breakthrough proteomics company specializing in the identification of disease footprints in the areas of chemotherapeutic drug resistance and the early detection of breast cancer and neurological diseases.
Power3 leverages its knowledge of proteomics to detect diseases earlier than currently thought possible. The focus of Power3’s efforts is on developing very sensitive patient tests that will enable doctors to diagnose and treat a disease before it becomes life-threatening or debilitating.
Every 72 seconds someone in America will develop Alzheimer�s. Current estimate is that 5.1 Million Americans have Alzheimer�s.
Death rate extrapolations for USA for Parkinson’s Disease: 14,593 per year, 1,216 per month, 280 per week, 39 per day, 1 per hour, 0 per minute, 0 per second.
1 in every 8 women will develop breast cancer. According to the World Health Organization, more than 1.2 million people will be diagnosed with breast cancer each year worldwide and over 500,000 will die from the disease.
Power3 uses technologies, know-how and proprietary techniques to focus on protein-based biomarkers, which are simply proteins that are significant in the diagnosis, monitoring or treatment of disease.
For on-target treatment with new medicines the need is to identify and assess the disease-related proteins and the healthy-related proteins. Only by specifying the precise differences between disease-related and healthy-related proteins can the development of a new diagnostic test to detect the disease, and new drugs to treat the disease effectively be done.
No comments:
Post a Comment